Clinical Trial Search

Primary: Phase 1b: Number of Participants Experiencing Dose Limiting Toxicity (DLT) According to National Cancer Institute Common Toxicity Criteria (NCI-CTCAE) for Adverse Events…

Primary: The Number of Patients in the Cohort Effectively Downstaged to Transplant Eligibility With the LC BeadTM

Primary: Rate of Adverse Events (AE) ≥ Grade 3 (CTCAE 5.0) Excluding Palmar-plantar Erythrodysesthesia — 16 Participants

Primary: Overall Survival — 333; 290 days — p=0.4593

Primary: Median Overall Survival (OS) Following Treatment With Tivantinib 120 mg BID Compared to Placebo Group in Participants With MET Diagnostic-High Inoperable Hepatocellular…

Primary: Number of Participants Who Remained Free of Progression at the 27th Week. — 21 participants — p=0.0006

Primary: Time to Progression (TTP) — 164; 112 days

Primary: Number of Participants With Objective Response Rate — 20; 9; 0; 1 Participants

Primary: Overall Response Rate — 6; 30; 17; 0 Participants

Primary: Median Radiographic Time to Progression (TTP) Calculated From Treatment Initiation to First Evidence of Disease Progression or Last Follow-up. — 6.7 months

Primary: Phase 1b: Number of Participants Experiencing Dose Limiting Toxicity — 0; 0; 0 Participants

Primary: Participants Without Recurrence (Disease-free). — 16; 28 Participants

Primary: Time to Progression (TTP) — 3.5 months

Primary: Disease Control Rate (DCR) at 16 Weeks for Patients Treated With Guadecitabine After Failure of Sorafenib — 25.0; 24.4 percentage of patients

Primary: Tumor Response — 0; 7; 47; 11 Participants

Primary: Percentage of Lesions With Organ-specific Response — 29.8; 28.3; 40.5; 29.1 Percentage of Units (lesions)

Primary: Time to Progression — 7.7 Months

Primary: Phase I: Maximum Tolerated Dose (MTD) of TRC105 When Given With Standard-dose Sorafenib for Hepatocellular Cancer (HCC) — 15 mg/kg

Primary: Number of Patients Demonstrating Somatostatin Receptor Positivity in Hepatocellular Carcinoma Using [68Ga]DOTATATE-PET — 0 Participants

Primary: Phase 1b: Number of Participants With Dose-limiting Toxicities (DLTs) — 1; 0 Participants

Primary: Number of Patients With DLTs — 0; 2; 1; 0 Participants

Primary: Overall Survival — 289; 259 Days

Primary: Overall Survival (OS) — 10.2; 8.0 months — p=0.0049

Primary: Number of Subjects With Overall Survival — 16; 4; 34; 24 Participants — p=0.536

Primary: Time to Progression-Blinded Independent Central Review (BICR) Assessment — 5.6; 4.1 Months — p=0.7382

Primary: Disease Control Rate (DCR) — 0; 0; 9 Participants

Primary: Disease Control Rate (DCR) in Study Participants — 46 percentage of participants

Primary: Overall Survival (OS) — 324; 241 days — p=0.00583

Primary: Correlation of HCC Stiffness to Overall Survival — 0.12 kilopascals — p=0.008

Primary: Progression Free Survival (PFS) Rate at 6 Months Per Independent Response Review Committee (IRRC) in Cohort A — 22.4 Percent of participants